| Gene Symbol |
ISG15
|
| Entrez Gene |
9636
|
| Alt Symbol |
G1P2, IFI15, IMD38, IP17, UCRP, hUCRP
|
| Species |
Human
|
| Gene Type |
protein-coding
|
| Description |
ISG15 ubiquitin-like modifier
|
| Other Description |
interferon, alpha-inducible protein (clone IFI-15K)|interferon-induced 17-kDa/15-kDa protein|interferon-stimulated protein, 15 kDa|ubiquitin cross-reactive protein|ubiquitin-like protein ISG15
|
| Swissprots |
Q7Z2G2 P05161 Q96GF0 Q5SVA4
|
| Accessions |
AAA36128 EAW56295 P05161 AY168648 AAN86983 BC009507 AAH09507 BM712238 BT007297 AAP35961 BU161226 DQ892714 ABM83640 EU176738 ABW03539 M13755 AAA36038 NM_005101 NP_005092
|
| Function |
Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation- inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA- induced JNK signaling. Exhibits antiviral activity towards
|
| Subcellular Location |
Cytoplasm {ECO:0000269|PubMed:22859821}. Secreted {ECO:0000269|PubMed:22859821}. Note=Exists in three distinct states: free within the cell, released into the extracellular space, or conjugated to target proteins.
|
| Tissue Specificity |
Detected in lymphoid cells, striated and smooth muscle, several epithelia and neurons. Expressed in neutrophils, monocytes and lymphocytes. Enhanced expression seen in pancreatic adenocarcinoma, endometrial cancer, and bladder cancer, as compared to non-cancerous tissue. In bladder cancer, the increase in expression exhibits a striking positive correlation with more advanced stages of the disease. {ECO:0000269|PubMed:22859821, ECO:0000269|PubMed:7490683}.
|
| Top Pathways |
RIG-I-like receptor signaling pathway
|
